Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan.

Yunokawa M, Sasada S, Takehara Y, Takahashi K, Shimoi T, Yonemori K, Ishikawa M, Kato T, Tamura K.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1051-1058. doi: 10.1007/s00280-019-03938-8. Epub 2019 Sep 4.

PMID:
31482227
2.

Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.

Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD.

Surg Oncol. 2019 Jun;29:25-32. doi: 10.1016/j.suronc.2019.02.002. Epub 2019 Feb 7.

PMID:
31196490
3.

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1), Singh N.

Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Review.

4.

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K.

Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8.

PMID:
31104192
5.

Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study.

Bun S, Yunokawa M, Ebata T, Kobayashi Kato M, Shimoi T, Kato T, Tamura K.

Int J Clin Oncol. 2019 Sep;24(9):1111-1118. doi: 10.1007/s10147-019-01449-3. Epub 2019 Apr 15.

PMID:
30993482
6.

Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.

Kobayashi-Kato M, Yunokawa M, Bun S, Miyasaka N, Kato T, Tamura K.

Cancer Chemother Pharmacol. 2019 Jul;84(1):33-39. doi: 10.1007/s00280-019-03834-1. Epub 2019 Apr 13.

PMID:
30982097
7.

The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).

Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I.

Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8.

PMID:
30853361
8.

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.

Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K.

Intern Med. 2019 May 15;58(10):1423-1428. doi: 10.2169/internalmedicine.1118-18. Epub 2019 Feb 1.

9.

A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma.

Takahashi K, Yunokawa M, Sasada S, Takehara Y, Miyasaka N, Kato T, Tamura K.

J Gynecol Oncol. 2019 Jan;30(1):e8. doi: 10.3802/jgo.2019.30.e8. Epub 2018 Oct 2.

10.

Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Surg Oncol. 2018 Sep;27(3):433-440. doi: 10.1016/j.suronc.2018.05.017. Epub 2018 May 11.

PMID:
30217299
11.

Clinical utility of CA-125 in the management of uterine carcinosarcoma.

Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD.

J Gynecol Oncol. 2018 Nov;29(6):e88. doi: 10.3802/jgo.2018.29.e88. No abstract available.

12.

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Ann Surg Oncol. 2018 Nov;25(12):3676-3684. doi: 10.1245/s10434-018-6695-z. Epub 2018 Aug 13.

PMID:
30105438
13.

Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Ann Surg Oncol. 2018 Sep;25(9):2756-2766. doi: 10.1245/s10434-018-6547-x. Epub 2018 Jul 3.

PMID:
29971677
14.

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.

Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K.

Cancer Sci. 2018 Aug;109(8):2558-2566. doi: 10.1111/cas.13696. Epub 2018 Jul 28.

15.

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.

Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S.

Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31.

16.

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Kodaira M, Yonemori K, Shimoi T, Yoshida A, Yoshida M, Kitano A, Shimomura A, Yunokawa M, Shimizu C, Takiguchi Y, Fujiwara Y, Tamura K.

BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.

17.

Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K.

Support Care Cancer. 2018 Jul;26(7):2161-2166. doi: 10.1007/s00520-018-4054-z. Epub 2018 Jan 25.

PMID:
29372396
18.

Significance of venous thromboembolism in women with uterine carcinosarcoma.

Matsuo K, Ross MS, Im DD, Klobocista MM, Bush SH, Johnson MS, Takano T, Blake EA, Ikeda Y, Nishimura M, Ueda Y, Shida M, Hasegawa K, Baba T, Adachi S, Yokoyama T, Satoh S, Machida H, Yanai S, Iwasaki K, Miyake TM, Takeuchi S, Takekuma M, Nagano T, Yunokawa M, Pejovic T, Omatsu K, Shahzad MMK, Kelley JL, Ueland FR, Roman LD.

Gynecol Oncol. 2018 Feb;148(2):267-274. doi: 10.1016/j.ygyno.2017.11.036. Epub 2017 Dec 13.

PMID:
29248197
19.

TERT promoter hotspot mutations in breast cancer.

Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K.

Breast Cancer. 2018 May;25(3):292-296. doi: 10.1007/s12282-017-0825-5. Epub 2017 Dec 8.

20.

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

BMC Cancer. 2017 Dec 4;17(1):819. doi: 10.1186/s12885-017-3846-8.

21.

Baseline risk of recurrence in stage I-II endometrial carcinoma.

Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, Tamura K.

J Gynecol Oncol. 2018 Jan;29(1):e9. doi: 10.3802/jgo.2018.29.e9.

22.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.

Inagaki C, Shimoi T, Okuma H, Kitano A, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Yoshida A, Fujiwara Y, Tamura K.

Anticancer Drugs. 2018 Jan;29(1):97-101. doi: 10.1097/CAD.0000000000000558.

PMID:
29176397
23.

Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.

Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MMK, Ueland FR, Kelley JL, Roman LD.

Gynecol Oncol. 2017 Dec;147(3):565-571. doi: 10.1016/j.ygyno.2017.10.008. Epub 2017 Oct 20.

PMID:
29056442
24.

Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.

Matsuo K, Johnson MS, Im DD, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Klobocista MM, Hasegawa K, Ueda Y, Shida M, Baba T, Satoh S, Yokoyama T, Machida H, Ikeda Y, Adachi S, Miyake TM, Iwasaki K, Yanai S, Takeuchi S, Nishimura M, Nagano T, Takekuma M, Shahzad MMK, Pejovic T, Omatsu K, Kelley JL, Ueland FR, Roman LD.

J Surg Oncol. 2018 Mar;117(3):488-496. doi: 10.1002/jso.24861. Epub 2017 Oct 16.

PMID:
29044542
25.

The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.

Ebata T, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Int J Gynecol Cancer. 2017 Nov;27(9):1850-1855. doi: 10.1097/IGC.0000000000001107.

PMID:
29040183
26.

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

Iizumi S, Shimoi T, Nishikawa T, Kitano A, Sasada S, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.

27.

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.

Hasegawa K, Kagabu M, Mizuno M, Oda K, Aoki D, Mabuchi S, Kamiura S, Yamaguchi S, Aoki Y, Saito T, Yunokawa M, Takehara K, Okamoto A, Ochiai K, Kimura T.

Invest New Drugs. 2017 Dec;35(6):800-812. doi: 10.1007/s10637-017-0504-6. Epub 2017 Sep 2.

PMID:
28864978
28.

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.

Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fujiwara Y, Tsuda H, Tamura K.

ESMO Open. 2017 May 2;2(2):e000150. doi: 10.1136/esmoopen-2016-000150. eCollection 2017.

29.

Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.

Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K.

Invest New Drugs. 2018 Feb;36(1):151-155. doi: 10.1007/s10637-017-0487-3. Epub 2017 Jul 21.

PMID:
28733700
30.

Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.

Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K.

Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.

31.

Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.

Yunokawa M, Yoshida H, Watanabe R, Noguchi E, Shimomura A, Shimoi T, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2017 Jul;80(1):127-134. doi: 10.1007/s00280-017-3342-5. Epub 2017 May 24.

PMID:
28540420
32.

Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.

Ebata T, Shimoi T, Ishiwata T, Iwasawa S, Bun S, Yunokawa M, Yonemori K, Takiguchi Y, Tamura K.

Oncology. 2017;93(3):177-182. doi: 10.1159/000475669. Epub 2017 May 19.

PMID:
28521313
33.

64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K.

Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227. No abstract available.

34.

Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy.

Tanabe Y, Tsuda H, Yoshida M, Yunokawa M, Yonemori K, Shimizu C, Yamamoto S, Kinoshita T, Fujiwara Y, Tamura K.

Cancer Sci. 2017 Jul;108(7):1520-1529. doi: 10.1111/cas.13274. Epub 2017 Jun 14.

35.

Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.

Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186. doi: 10.1007/s00280-017-3314-9. Epub 2017 Apr 26.

PMID:
28447211
36.

Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.

Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, Im DD, Bush SH, Ueda Y, Takano T, Blake EA, Hasegawa K, Baba T, Shida M, Satoh S, Yokoyama T, Machida H, Adachi S, Ikeda Y, Iwasaki K, Miyake TM, Yanai S, Nishimura M, Nagano T, Takekuma M, Takeuchi S, Pejovic T, Shahzad MM, Ueland FR, Kelley JL, Roman LD.

Gynecol Oncol. 2017 Apr;145(1):78-87. doi: 10.1016/j.ygyno.2017.02.001. Epub 2017 Feb 16.

PMID:
28215838
37.

Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.

Matsuo K, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Ueda Y, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Takeuchi S, Nishimura M, Iwasaki K, Yanai S, Klobocista MM, Johnson MS, Machida H, Hasegawa K, Miyake TM, Nagano T, Pejovic T, Shahzad MM, Im DD, Omatsu K, Ueland FR, Kelley JL, Roman LD.

Gynecol Oncol. 2017 Feb;144(2):329-335. doi: 10.1016/j.ygyno.2016.11.042. Epub 2016 Dec 5.

PMID:
27931750
38.

Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.

Ebata T, Yunokawa M, Bun S, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1283-1288. doi: 10.1007/s00280-016-3187-3. Epub 2016 Nov 10.

PMID:
27832327
39.

Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.

Bun S, Yunokawa M, Ebata T, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Makino Y, Hayashi Y, Tamura K.

Cancer Chemother Pharmacol. 2016 Oct;78(4):745-52. doi: 10.1007/s00280-016-3100-0. Epub 2016 Aug 13.

PMID:
27522647
40.

Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.

Sawada T, Araki J, Yamashita T, Masubuchi M, Chiyoda T, Yunokawa M, Hoshi K, Tao S, Yamamura S, Yatsushiro S, Abe K, Kataoka M, Shimoyama T, Maeda Y, Kuroi K, Tamura K, Sawazumi T, Minami H, Suda Y, Koizumi F.

EBioMedicine. 2016 Sep;11:173-182. doi: 10.1016/j.ebiom.2016.07.027. Epub 2016 Jul 27.

41.

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.

Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Br J Cancer. 2016 Aug 9;115(4):411-9. doi: 10.1038/bjc.2016.184. Epub 2016 Jul 14.

42.

Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults.

Sasada S, Kodaira M, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Anticancer Res. 2016 May;36(5):2429-32.

PMID:
27127153
43.

Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.

Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.

Gynecol Oncol. 2016 Jun;141(3):447-453. doi: 10.1016/j.ygyno.2016.04.004. Epub 2016 Apr 14.

PMID:
27072806
44.

Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Ann Oncol. 2016 Jul;27(7):1257-66. doi: 10.1093/annonc/mdw161. Epub 2016 Apr 6.

45.

Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.

Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K.

Oncologist. 2016 Apr;21(4):508-13. doi: 10.1634/theoncologist.2015-0377. Epub 2016 Mar 14.

46.

Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.

Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T, Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y, Koizumi F.

Cancer Sci. 2016 Mar;107(3):307-14. doi: 10.1111/cas.12868. Epub 2016 Feb 23.

47.

Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.

Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.

Int J Clin Oncol. 2016 Feb;21(1):168-76. doi: 10.1007/s10147-015-0859-7. Epub 2015 Jun 18.

PMID:
26084780
48.

Molecular imaging using PET for breast cancer.

Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M, Yunokawa M, Yamamoto H, Watanabe Y, Fujiwara Y, Tamura K.

Breast Cancer. 2016 Jan;23(1):24-32. doi: 10.1007/s12282-015-0613-z. Epub 2015 Apr 28. Review.

PMID:
25917108
49.

Back with a vengeance: microvascular tumor embolism.

Yunokawa M, Tsuta K, Tanaka T, Nara E, Koizumi F, Ito J, Sekine S, Fujiwara Y, Tamura K.

Am J Med. 2015 Aug;128(8):834-6. doi: 10.1016/j.amjmed.2015.04.004. Epub 2015 Apr 23. No abstract available.

PMID:
25912204
50.

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K.

EJNMMI Res. 2015 Mar 12;5:8. doi: 10.1186/s13550-015-0082-6. eCollection 2015.

Supplemental Content

Loading ...
Support Center